Tessera
Folgen

Sandra Castillo

@sandradcastillo.bsky.social

RyC Researcher at Institut de Recerca Sant Joan de Déu, Pediatric Cancer Center Barcelona. Vascular Malformations & Tumours | Rare diseases | Genetics | Cell Signalling 👩🏻‍🔬🧬🧫🔬 https://www.irsjd.org/en/people/staff/1367/sandra-castillo-diez

4 Posts224 Follower516 Folgt
Sandra Castillo@sandradcastillo.bsky.social · last yr.

We’re happy 😄 to share our latest work in Cancer Discov @theaacr.bsky.social – we discover that PTEN UPD 🧬 in endothelial cells causes vascular malformations in PTEN Hamartoma Tumor Syndrome (PHTS), create a new mouse model 🐀 & test PI3K signaling inhibitors 💊. aacrjournals.org/cancerdiscov...

Somatic uniparental disomy of PTEN in endothelial cells causes vascular malformations in patients with PTEN Hamartoma Tumor Syndrome

Abstract. PTEN Hamartoma Tumor Syndrome (PHTS) is a rare tumor risk disorder caused by germline loss-of-function mutations in PTEN. Half of these patients develop vascular malformations, a hamartoma c...

aacrjournals.org

Mariona Graupera@grauperalab.bsky.social · last yr.

We are excited to share our work on Context-dependent response of endothelial cells to PIK3CA mutation. A tour the force of many; thank you all for your invaluable contribution. @aangulou.bsky.social @ruibenedito.bsky.social @debocklab.bsky.social @sandradcastillo.bsky.social bit.ly/4blKSqa

Context-dependent response of endothelial cells to PIK3CA mutation

Cancer mutations in the PIK3CA gene cause congenital disorders. The endothelium is among the most frequently affected tissues in these disorders, displaying aberrant vascular overgrowth in the form of...

bit.ly

IRB Barcelona@irbbarcelona.org · 2y ago

📰 #IRBBarcelona spin-off #Gate2Brain receives European Medicines Agency (EMA) Orphan Drug Designation for its #PediatricCancer treatment. 🗣️Meritxell Teixidó (CEO): "We are moving toward clinical trials that could transform the treatment of pediatric brain tumors". ➡️ bit.ly/4fLmnEb #Innovation 🧪

Gate2Brain Receives EMA Orphan Drug Designation for Its Pediatric Cancer Treatment

The IRB Barcelona spin-off Gate2Brain, a cutting-edge technology platform focused on enhancing drug delivery to the brain, has reached a major milestone in the fight against pediatric brain tumors by ...

bit.ly